Company Analysis
Sign in

Oric Pharmaceuticals, Inc. (ORIC)

Nasdaq: ORIC · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2019
Full chart Alerts Compare
Grade5.3
◀ Past 5.5● Present 6.1▶ Future 4.3
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

18 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Oric Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
18
18 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 2 in 2024 and 2 in 2023
Applications published
34
3 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals9
Organic fine chemistry6
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
ORIC Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
0 granted
34 published
ORIC PHARMACEUTICALS, INC. its own name
US, as the owner printed on each patent
18 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 28, 202512,454,544CD73 inhibitorsPharmaceuticalsORIC PHARMACEUTICALS, INC.
May 27, 202512,312,339Polo like kinase 4 inhibitorsOrganic fine chemistryORIC PHARMACEUTICALS, INC.
Jun 25, 202412,018,043CD73 inhibitorsPharmaceuticalsORIC PHARMACEUTICALS, INC.
Jan 2, 202411,858,915Polo like kinase 4 inhibitorsOrganic fine chemistryORIC PHARMACEUTICALS, INC.
Nov 7, 202311,807,658CD73 inhibitorsOrganic fine chemistryORIC PHARMACEUTICALS, INC.
Feb 14, 202311,576,922CD73 inhibitorsPharmaceuticalsORIC PHARMACEUTICALS, INC.
Dec 20, 202211,530,236CD73 inhibitorsPharmaceuticalsORIC PHARMACEUTICALS, INC.
Jul 5, 202211,377,469CD73 inhibitorsPharmaceuticalsORIC PHARMACEUTICALS, INC.
May 10, 202211,325,938CD73 inhibitorsOrganic fine chemistryORIC PHARMACEUTICALS, INC.
Dec 28, 202111,208,432Inhibitors of glucocorticoid receptorOrganic fine chemistryORIC PHARMACEUTICALS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 4, 20252025/0368677CD73 INHIBITORSOrganic fine chemistryORIC Pharmaceuticals, Inc.
Jan 30, 20252025/0034198CD73 INHIBITORSPharmaceuticalsORIC Pharmaceuticals, Inc. · patent 12,454,544 granted from it
Jan 30, 20252025/0034159INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTORPharmaceuticalsORIC Pharmaceuticals, Inc.
Dec 5, 20242024/0398811PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERSPharmaceuticalsORIC Pharmaceuticals, Inc.
Aug 15, 20242024/0270722POLO LIKE KINASE 4 INHIBITORSOrganic fine chemistryORIC Pharmaceuticals, Inc.
Apr 18, 20242024/0124512CD73 INHIBITORSOrganic fine chemistryORIC Pharmaceuticals, Inc.
Apr 18, 20242024/0124426POLO LIKE KINASE 4 INHIBITORSOrganic fine chemistryORIC Pharmaceuticals, Inc. · patent 12,312,339 granted from it
Nov 16, 20232023/0365537POLO LIKE KINASE 4 INHIBITORSOrganic fine chemistryORIC Pharmaceuticals, Inc. · patent 11,858,915 granted from it
Sep 28, 20232023/0302014USES OF GLUCOCORTICOID RECEPTOR (GR) ANTAGONIST AND ANDROGEN RECEPTOR (AR) DEGRADER COMBINATIONSPharmaceuticalsORIC Pharmaceuticals, Inc.
Apr 27, 20232023/0131747CD73 INHIBITORSPharmaceuticalsORIC Pharmaceuticals, Inc. · patent 12,018,043 granted from it
What it applied for, 2024 to 2025: Organic fine chemistry 4 · Pharmaceuticals 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ORIC · research, not advice